RxDoctor Payments Data

Garrett Fratesi, DO

Family Medicine · Diamondhead, MSNPI 1427673532

Payments from drug & device makers

$1,944in general payments, 2019–2025

Across 82 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$623
  • AstraZeneca$328
  • Lilly USA, LLC$266
  • Novo Nordisk$159
  • Exact Sciences$126
  • Amgen$124
  • plus $318 from 10 others

What the payments were for

  • Food & beverage$1,944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,944 in reported general payments places this provider in the 65th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$102,348
Medicare patients
235
Services billed
1,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$64,906
MounjaroTirzepatide40$55,896
OzempicSemaglutide43$53,753
EliquisApixaban43$40,057
RybelsusSemaglutide20$38,295
FarxigaDapagliflozin Propanediol38$32,353
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,307
KerendiaFinerenone14$14,122
XareltoRivaroxaban20$12,500
Breo ElliptaFluticasone/Vilanterol12$5,808
SymbicortBudesonide/Formoterol Fumarate16$4,448
Albuterol Sulfate HfaAlbuterol Sulfate73$1,814
Baclofen106$1,698
Tamsulosin Hcl149$1,391
Rosuvastatin Calcium215$1,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$159$92,04863 claims
Lilly USA, LLCMounjaro$266$55,89640 claims
PfizerEliquis$11$40,05743 claims
AstraZenecaFarxiga, Symbicort$328$36,80154 claims
GSKTrelegy Ellipta, Breo Ellipta$48$26,11534 claims
BayerKerendia$60$14,12214 claims
Johnson & JohnsonXarelto$23$12,50020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Diamondhead

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →